Price movement over the last 24 hours
Alcon AG vs Novartis AG — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Novartis AG trades at $155.41 (market cap $298.98B). The key difference: Novartis AG is far larger — about 9.1× Alcon AG's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| ALC | NVS | |
|---|---|---|
Market Cap | $32.69B | $298.98B |
Sector | Health | Health |
52-Week High | $92.22 | $168.62 |
52-Week Low | $62.02 | $113.50 |
Enterprise Value | $36.28B | $339.00B |
Dividend Yield | 0.54% | 3.02% |
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →